Insider Selling: Tempus AI (NASDAQ:TEM) EVP Sells 8,143 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 8,143 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $480,844.15. Following the completion of the transaction, the executive vice president owned 99,447 shares of the company’s stock, valued at $5,872,345.35. This represents a 7.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Polovin also recently made the following trade(s):

• On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19.
• On Monday, November 24th, Andrew Polovin sold 12,874 shares of Tempus AI stock. The stock was sold at an average price of $75.00, for a total value of $965,550.00.

Tempus AI Price Performance

NASDAQ TEM traded down $1.59 during mid-day trading on Friday, hitting $58.37. The stock had a trading volume of 7,883,470 shares, compared to its average volume of 5,746,147. The company has a 50 day simple moving average of $62.60 and a 200 day simple moving average of $73.38. The company has a market cap of $10.38 billion, a price-to-earnings ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in TEM. Victory Capital Management Inc. boosted its position in Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares during the period. Global Retirement Partners LLC raised its position in Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after purchasing an additional 167 shares during the period. US Bancorp DE lifted its stake in shares of Tempus AI by 6.6% during the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after purchasing an additional 176 shares in the last quarter. Legacy Bridge LLC boosted its position in shares of Tempus AI by 1.6% in the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after buying an additional 193 shares during the period. Finally, Truist Financial Corp boosted its position in shares of Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after buying an additional 194 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Robert W. Baird started coverage on shares of Tempus AI in a research note on Tuesday. They set an “outperform” rating and a $59.00 price objective on the stock. Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Needham & Company LLC increased their price target on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $85.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.